Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-25

Study Completion Date

2021-03-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with acute myeloid leukemia(AML) recurred after the allogeneic hematopoietic stem cell transplantation (allo-HSCT) have a dismal prognosis.The investigators developed donor-derived chimeric antigen receptor modified-T cell(CART) to target CD123 for the treatment of AML. The investigators start the Phase I study aimed to treat recurred post-transplantation AML patients using donor-derived CAR-T. The purpose of this study is to assess the safety and effectiveness of anti-CD123 CAR-T cells in patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML）

NCT03556982

Leukemia, Myeloid, Acute

UNKNOWN PHASE1/PHASE2

Allogeneic CART-33 for Relapsed/Refractory CD33+ AML

NCT02799680

Relapsed and/or Refractory CD33+ AML

UNKNOWN PHASE1

Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33

NCT01864902

Relapsed Adult Myeloid Leukemia Chemotherapy Refractory Adult Myeloid Leukemia

UNKNOWN PHASE1/PHASE2

CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia

NCT04265963

Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute

UNKNOWN PHASE1/PHASE2

Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia

NCT02186860

Acute Lymphoblastic Leukemia

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Allo-HSCT is increasingly being used for AML, however, leukemia relapse remain a main problem for decades.Recently the investigators have witnessed great progresses in cancer therapy with chimeric antigen receptors modified T cells(CAR-T), especially for B-cell malignance. preclinical data about anti-CD123 CART have shown raised serious safety concerns of human anti-CD123 CAR-T for severe impairment of normal hematopoiesis in NSG mice.Patients with AML recurred after allo-HSCT have a dismal prognosis.The investigators developed donor-derived CART to target CD123 for the treatment of AML. The investigators start the Phase I study aimed to recurred post-transplantation AML patients using donor-derived CAR-T. The purpose of this study is to assess the safety and effectiveness of anti-CD123 CAR-T cells in patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adult Acute Myeloid Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells

Patients will receive a full dose CART infusion at day 0.

Group Type EXPERIMENTAL

CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells

Intervention Type BIOLOGICAL

a single dose of CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells will be infusion after preconditioning.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells

a single dose of CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells will be infusion after preconditioning.

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

anti-CD123 CART, CART123

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and Female subjects with CD123+ acute myeloid leukemia as confirmed by immunohistochemistry and flow cytometry;
2. Patients must have received an allogenic stem cell transplantation(Allo-HSCT). The leukemia relapsed. There are available donor or enough cryopreserved donor-derived PBMCs for CART preparation and subsequent Allo-HSCT. In the previous case, the donor should have adequate venous access for apheresis.
3. Karnofsky score greater than 70%;
4. patients more than 18 years of age
5. Expected survival time \>16 weeks;
6. Bilirubin \<3.0 mg/dL,
7. Alanine aminotransferase(ALT)/ aspartate aminotransferase(AST)\<3 fold normal.
8. Diffusing capacity of the lung for carbon monoxide(DLCO) and forced expiratory volume in one second(FEV1)\>45% of predictive value.
9. At least received three kinds of medicines functioning by different mechanisms, including alkylating agents, protease inhibitors, and immunomodulators, and disease progressing within 60 days.
10. Important organs are well tolerated;
11. For post-transplantation patients, the apheresis would be undertaken only at least 2 weeks after immunosuppressive agents for GvHD withdrawal;
12. From very beginning of the test to 30 days after the withdrawal, men and women should adopt reliable contraceptive measures.
13. All research participants must have the ability to understand and willingness to sign a written informed consent.

Exclusion Criteria

1. Patients were diagnosed with APL M3:t(15; 17)(q22; q12);PML/RARα ）；
2. Symptomatic active central nervous system leukaemia;
3. Patients with HIV, hepatitis B or C infection;
4. Any concurrent active malignancies;
5. Other uncontrolled active illness that hinders participation in the trial;
6. Patients suffer from coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, cerebral thrombosis, cerebral hemorrhage and other serious heart, cerebrovascular disease;
7. patients with poorly controlled hypertensive
8. patients with froward psychiatric history
9. anyone who the researchers think unsuitable to participate in the investigation;
10. anyone who long-term use of immunosuppressive agents for organ transplants or other reasons, or undertake inhaled corticosteroids therapy recently.
11. failed production release testing: CAR+ T cells \<30% or T cell expansion less than 5-fold under the CD3/28 beads stimulation.
12. Pregnant, lactating or female patients planning to get pregnant within 2 months before treatment ends;

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No